RICHMOND, British Columbia--(BUSINESS WIRE)--April 12, 2006--BioCurex Inc. (Pink Sheets:BOCX - News) announced today that its RECAF blood test for cancer is able to detect very early stages of breast cancer with a high degree of accuracy. The study was blinded in that the actual diagnosis was not disclosed to BioCurex until after the test was performed. All samples were verified as early stage cancers -- Stage I and Stage II. (There are four stages of cancer identifying the progression of the disease).
